PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30422238-5 2018 One hundred twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene therapy for at least 3 months were enrolled. Bexarotene 85-95 TSPY like 2 Homo sapiens 63-67 30422238-1 2018 Importance: Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Bexarotene 85-95 TSPY like 2 Homo sapiens 134-138 30422238-13 2018 Conclusions and Relevance: These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile. Bexarotene 170-180 TSPY like 2 Homo sapiens 208-212 24732904-1 2016 Bexarotene, a synthetic retinoid licensed for the treatment of refractory cutaneous T-cell lymphoma (CTCL), has been used clinically in Poland since 2007 in 21 patients. Bexarotene 0-10 TSPY like 2 Homo sapiens 101-105 30294626-1 2018 This article presents the experimental data supporting analysis of differential gene expression of human cutaneous T cell lymphoma (CTCL) cell culture cells (Hut78) treated with bexarotene or a variety of rexinoids, in conjunction with "A Novel Gene Expression Analytics-based Approach to Structure Aided Design of Rexinoids for Development as Next-Generation Cancer Therapeutics" (Hanish et al. Bexarotene 178-188 TSPY like 2 Homo sapiens 132-136 29704526-2 2018 However, only one rexinoid, bexarotene (Targretin TM) has been successfully transitioned from the bench to the clinic and used to treat cutaneous T-cell lymphoma (CTCL). Bexarotene 28-38 TSPY like 2 Homo sapiens 163-167 29521139-2 2018 Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL). Bexarotene 0-10 TSPY like 2 Homo sapiens 134-138 28748653-10 2017 Our report is the second to describe PT-CTCL demonstrating a long-term complete response to oral bexarotene. Bexarotene 97-107 TSPY like 2 Homo sapiens 40-44 28748653-11 2017 Given its anti-carcinogenic properties and favorable toxicity profile, oral bexarotene represents an appealing treatment option for PT-CTCL refractory to skin-directed therapies. Bexarotene 76-86 TSPY like 2 Homo sapiens 135-139 28319634-2 2017 We report a rare case of a patient with cutaneous T-cell lymphoma (CTCL) who developed profound CD4 lymphopenia in the setting of long-term bexarotene therapy. Bexarotene 140-150 TSPY like 2 Homo sapiens 67-71 28319634-3 2017 Bexarotene is a third-generation retinoid that inhibits epithelial cell proliferation and is approved for treatment of advanced CTCL (stages IIB-IVB) in adult patients who have failed at least 1 prior systemic therapy. Bexarotene 0-10 TSPY like 2 Homo sapiens 128-132 24732904-11 2016 Based on the results of our analysis, bexarotene is a valuable tool in the treatment of refractory early-stage CTCL. Bexarotene 38-48 TSPY like 2 Homo sapiens 111-115 23968145-1 2014 BACKGROUND: Topical bexarotene 1% gel is currently FDA-approved for early stage (IA and IB) persistent or refractory cutaneous T-cell lymphoma (CTCL). Bexarotene 20-30 TSPY like 2 Homo sapiens 144-148 26811014-4 2016 Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Bexarotene 102-112 TSPY like 2 Homo sapiens 68-72 26332008-2 2016 Bexarotene gel is a topical retinoid used in the treatment of CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 62-66 26687705-1 2015 CONTEXT: Bexarotene is a retinoid X receptor agonist, which is currently used for the treatment of cutaneous T-cell lymphoma (CTCL). Bexarotene 9-19 TSPY like 2 Homo sapiens 126-130 26687705-7 2015 Bexarotene was discontinued due to poor response of CTCL, 3 months after which her HDL-C levels returned to baseline of 80 to 90 mg/dL (2.07-2.33 mmol/L). Bexarotene 0-10 TSPY like 2 Homo sapiens 52-56 26012882-2 2015 All-trans-retinoic acid, the natural ligand for RARs, is used therapeutically for the treatment of acute promyelocytic leukemia (APL), whereas the synthetic rexinoid bexarotene (a representative member of the aromatic retinoids or arotinoids) is approved for the treatment of cutaneous T-cell lymphoma (CTCL). Bexarotene 166-176 TSPY like 2 Homo sapiens 303-307 25826424-6 2015 Here we provide evidence that retinoids, including Bexarotene, selectively induce CTCL lineages to increase integrin beta7 expression and function prior to growth arrest and apoptosis. Bexarotene 51-61 TSPY like 2 Homo sapiens 82-86 26451138-1 2015 The retinoid x receptors (RXRs) are the pharmacological target of Bexarotene, an antineoplastic agent indicated for the treatment of cutaneous T cell lymphoma (CTCL). Bexarotene 66-76 TSPY like 2 Homo sapiens 160-164 24136145-1 2013 BACKGROUND: Both gemcitabine and bexarotene are established single agents for the treatment of cutaneous T-cell lymphoma (CTCL). Bexarotene 33-43 TSPY like 2 Homo sapiens 122-126 24285015-2 2014 Approximately 50% of CTCL patients respond to bexarotene (Bex). Bexarotene 46-56 TSPY like 2 Homo sapiens 21-25 24285015-2 2014 Approximately 50% of CTCL patients respond to bexarotene (Bex). Bexarotene 58-61 TSPY like 2 Homo sapiens 21-25 23557425-6 2013 Bexarotene is the first retinoid approved by the US FDA for CTCL therapy. Bexarotene 0-10 TSPY like 2 Homo sapiens 60-64 23837676-1 2013 BACKGROUND: Bexarotene was approved for cutaneous T-cell lymphoma (CTCL) in 1999. Bexarotene 12-22 TSPY like 2 Homo sapiens 67-71 23837676-2 2013 Apart from the two first clinical trials published ten years ago, very few data were published on the long-term use of bexarotene in CTCL patients. Bexarotene 119-129 TSPY like 2 Homo sapiens 133-137 23837676-3 2013 OBJECTIVES: We performed a retrospective review of CTCL patients treated with bexarotene at a single skin Cancer department between 2002 and 2012. Bexarotene 78-88 TSPY like 2 Homo sapiens 51-55 23837676-4 2013 We aimed to determine retrospectively the long-term tolerability and outcome of bexarotene in a cohort of CTCL patients and to compare these results with data from the literature. Bexarotene 80-90 TSPY like 2 Homo sapiens 106-110 23837676-10 2013 CONCLUSIONS: This study with a very long observation time confirms that bexarotene is well tolerated by CTCL patients during long-term use. Bexarotene 72-82 TSPY like 2 Homo sapiens 104-108 24278042-4 2013 Orally administrated bexarotene, the first synthetic selective RXR retinoid, was revealed to be active against the cutaneous manifestation of CTCL. Bexarotene 21-31 TSPY like 2 Homo sapiens 142-146 22917895-1 2013 BACKGROUND: Bexarotene is the only Food and Drug Administration-approved retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) and is associated with a relatively high frequency of adverse effects. Bexarotene 12-22 TSPY like 2 Homo sapiens 130-134 23149703-0 2012 Combination treatment in CTCL: the current role of bexarotene. Bexarotene 51-61 TSPY like 2 Homo sapiens 25-29 22963233-12 2013 CONCLUSION: Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose. Bexarotene 37-47 TSPY like 2 Homo sapiens 66-70 18559673-1 2008 The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL). Bexarotene 18-28 TSPY like 2 Homo sapiens 101-105 22678563-1 2012 Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lym-phoma (CTCL). Bexarotene 0-10 TSPY like 2 Homo sapiens 118-122 22678563-3 2012 We present here data on 37 Finnish patients with CTCL treated with bexarotene during the last 10 years. Bexarotene 67-77 TSPY like 2 Homo sapiens 49-53 21461579-5 2011 The RXR family plays a role in cell differentiation and proliferation and is known to be the target of bexarotene, which is used in the treatment of CTCL. Bexarotene 103-113 TSPY like 2 Homo sapiens 149-153 19845753-0 2010 About the cutaneous targets of bexarotene in CTCL patients. Bexarotene 31-41 TSPY like 2 Homo sapiens 45-49 19845753-7 2010 The main bexarotene"s target thus remains T-cells by inducing their apoptosis, a mechanism that is different from the other retinoids used in CTCL. Bexarotene 9-19 TSPY like 2 Homo sapiens 142-146 19845755-3 2010 Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy. Bexarotene 0-10 TSPY like 2 Homo sapiens 111-115 19845755-4 2010 Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease despite improvement of cutaneous signs and symptoms were reported. Bexarotene 47-57 TSPY like 2 Homo sapiens 70-74 20484880-2 2010 METHODS: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Bexarotene 94-104 TSPY like 2 Homo sapiens 75-79 20484880-10 2010 CONCLUSION: This is the first study on the evolution of the T-cell clone in blood and skin in CTCL patients during bexarotene therapy. Bexarotene 115-125 TSPY like 2 Homo sapiens 94-98 19222457-1 2009 BACKGROUND: Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL). Bexarotene 12-22 TSPY like 2 Homo sapiens 145-149 19222457-1 2009 BACKGROUND: Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL). Bexarotene 24-33 TSPY like 2 Homo sapiens 145-149 19222457-2 2009 OBJECTIVES: To summarize our experience with bexarotene for patients with CTCL with the aim of assessing efficacy and safety. Bexarotene 45-55 TSPY like 2 Homo sapiens 74-78 19016373-3 2009 OBJECTIVE: To evaluate the efficacy and safety of an oral bexarotene and methotrexate combination for the treatment of refractory CTCL. Bexarotene 58-68 TSPY like 2 Homo sapiens 130-134 19016373-4 2009 METHOD: A retrospective study was carried out of 12 patients with refractory stage CTCL treated with an oral combination of bexarotene and methotrexate from 2000 to 2007. Bexarotene 124-134 TSPY like 2 Homo sapiens 83-87 19016373-5 2009 RESULTS: Twelve patients with CTCL stage IA-IIB disease who received a combination of bexarotene and methotrexate were identified. Bexarotene 86-96 TSPY like 2 Homo sapiens 30-34 19016373-13 2009 CONCLUSION: An oral bexarotene and methotrexate combination may be a promising future alternative to monotherapy for the treatment of CTCL, but further studies are required. Bexarotene 20-30 TSPY like 2 Homo sapiens 134-138 21547336-1 2011 Bexarotene (Targretin( )), was registered for the treatment of cutaneous T-cell lymphoma (CTCL) in 2002, and has been reported to induce a 45% overall response. Bexarotene 0-10 TSPY like 2 Homo sapiens 90-94 21547336-1 2011 Bexarotene (Targretin( )), was registered for the treatment of cutaneous T-cell lymphoma (CTCL) in 2002, and has been reported to induce a 45% overall response. Bexarotene 12-21 TSPY like 2 Homo sapiens 90-94 21547336-3 2011 This study explored the usefulness of a novel cancer-associated gene, NAV3 and corresponding chromosome 12 copy numbers as possible biomarkers to monitor the therapeutic response to bexarotene in 21 Finnish patients with CTCL. Bexarotene 182-192 TSPY like 2 Homo sapiens 221-225 18559673-1 2008 The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL). Bexarotene 30-39 TSPY like 2 Homo sapiens 101-105 17763605-6 2007 Bexarotene is indicated in CTCL patients who are refractory to at least one prior systemic therapy. Bexarotene 0-10 TSPY like 2 Homo sapiens 27-31 18615708-2 2008 Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 54-58 18615708-3 2008 Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene. Bexarotene 86-96 TSPY like 2 Homo sapiens 42-46 18405187-0 2008 Bexarotene monotherapy for epidermotropic CD8+ CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 47-51 17553039-4 2007 Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced-stage CTCL and in the U.S.A. for refractory CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 140-144 17553039-4 2007 Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced-stage CTCL and in the U.S.A. for refractory CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 178-182 17553039-5 2007 We provide guidance on the use of bexarotene in the management of CTCL, based on data from phase II/III clinical trials and the authors" clinical experience, and suggest how the potential of the drug can be maximized. Bexarotene 34-44 TSPY like 2 Homo sapiens 66-70 17553039-6 2007 The clinical trial results with bexarotene are reviewed, especially in comparison with interferon-alpha, which is the other commonly used noncytotoxic systemic therapy for CTCL. Bexarotene 32-42 TSPY like 2 Homo sapiens 172-176 17553039-7 2007 A treatment algorithm for bexarotene in refractory CTCL is suggested. Bexarotene 26-36 TSPY like 2 Homo sapiens 51-55 17553039-10 2007 We conclude that bexarotene is effective in the management of CTCL, and has the advantage of oral administration. Bexarotene 17-27 TSPY like 2 Homo sapiens 62-66 17474355-7 2007 The synthetic retinoid bexarotene (Targretin) is taken orally and produces high response rates in CTCL, with a good long-term tolerability profile. Bexarotene 23-33 TSPY like 2 Homo sapiens 98-102 17366595-1 2007 BACKGROUND: Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T-cell lymphoma (CTCL). Bexarotene 12-22 TSPY like 2 Homo sapiens 135-139 17474355-7 2007 The synthetic retinoid bexarotene (Targretin) is taken orally and produces high response rates in CTCL, with a good long-term tolerability profile. Bexarotene 35-44 TSPY like 2 Homo sapiens 98-102 17014481-3 2006 Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. Bexarotene 20-30 TSPY like 2 Homo sapiens 153-157 17014481-3 2006 Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. Bexarotene 20-30 TSPY like 2 Homo sapiens 236-240 16734503-7 2006 Recent novel developments include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL and has been shown to be effective in patients with refractory early-stage disease as well as advanced-stage disease. Bexarotene 39-49 TSPY like 2 Homo sapiens 127-131 16882161-1 2006 Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies. Bexarotene 0-10 TSPY like 2 Homo sapiens 130-134 16882161-3 2006 A pragmatic strategy for minimizing bexarotene-associated hypertriglyceridaemia and hypothyroidism is suggested, based on data from the studies with bexarotene in CTCL and on day-to-day experience with this agent in the clinical setting. Bexarotene 36-46 TSPY like 2 Homo sapiens 163-167 16844539-0 2006 Bexarotene and systemic disease progression in CTCL? Bexarotene 0-10 TSPY like 2 Homo sapiens 47-51 16734503-9 2006 Oral bexarotene and topical bexarotene have been approved by the US FDA for the treatment of refractory CTCL. Bexarotene 5-15 TSPY like 2 Homo sapiens 104-108 16734503-9 2006 Oral bexarotene and topical bexarotene have been approved by the US FDA for the treatment of refractory CTCL. Bexarotene 28-38 TSPY like 2 Homo sapiens 104-108 12006543-1 2002 PURPOSE: Bexarotene is the first synthetic rexinoid approved for the treatment of all stages of cutaneous T-cell lymphoma (CTCL) however the mechanism of bexarotene action is unknown. Bexarotene 9-19 TSPY like 2 Homo sapiens 123-127 15202526-7 2003 Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL. Bexarotene 38-48 TSPY like 2 Homo sapiens 30-34 15202526-7 2003 Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL. Bexarotene 38-48 TSPY like 2 Homo sapiens 152-156 15948982-1 2005 BACKGROUND: Apoptosis of malignant cells has been suggested as an important mechanism of the action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL). Bexarotene 103-113 TSPY like 2 Homo sapiens 161-165 15663654-1 2005 BACKGROUND: A 63-year-old man with therapy-resistant Sezary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced-stage cutaneous T-cell lymphoma (CTCL). Bexarotene 113-123 TSPY like 2 Homo sapiens 170-174 15663654-8 2005 Further studies on the interaction between the skin, lymph nodes, and peripheral blood compartments during bexarotene treatment in this subset of patients with CTCL are needed. Bexarotene 107-117 TSPY like 2 Homo sapiens 160-164 15389192-2 2004 OBJECTIVE: To evaluate the efficacy of combination therapy with bexarotene and psoralen plus ultraviolet A (PUVA) in treating patients with cutaneous T-cell lymphoma (CTCL) that recurred following monotherapy with multiple agents, including electron-beam irradiation, interferon, PUVA, and topical steroids. Bexarotene 64-74 TSPY like 2 Homo sapiens 167-171 15389192-4 2004 METHODS: Retrospective chart review analysis of eight patients with CTCL ranging from stage Ia to IIb who failed multiple single-agent treatment regimens treated with low-dose oral bexarotene and PUVA combination therapy. Bexarotene 181-191 TSPY like 2 Homo sapiens 68-72 15389192-6 2004 CONCLUSION: In view of its good safety profile, combination therapy with bexarotene and PUVA may be considered for patients with treatment resistant CTCL refractory to monotherapy. Bexarotene 73-83 TSPY like 2 Homo sapiens 149-153 14988678-2 2004 In December 1999 a new retinoid, bexarotene, was approved by the US Food and Drug Administration for the treatment of CTCL. Bexarotene 33-43 TSPY like 2 Homo sapiens 118-122 14988678-3 2004 At the manufacturer"s recommended dose of bexarotene (300 mg/m(2) of body surface area), it has proven to be a highly effective therapy for all stages of CTCL. Bexarotene 42-52 TSPY like 2 Homo sapiens 154-158 12852367-6 2003 In clinical trials, bexarotene gel demonstrated efficacy for the topical treatment of cutaneous lesions in patients with stage IA or IB CTCL who have refractory or persistent disease following other therapies or who cannot tolerate other therapies. Bexarotene 20-30 TSPY like 2 Homo sapiens 136-140 12852367-10 2003 The availability of bexarotene gel provides patients and physicians with a new skin-directed treatment option for early stage CTCL. Bexarotene 20-30 TSPY like 2 Homo sapiens 126-130 14686975-3 2003 Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. Bexarotene 20-30 TSPY like 2 Homo sapiens 128-132 14686975-3 2003 Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. Bexarotene 20-30 TSPY like 2 Homo sapiens 211-215 14686975-5 2003 Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis. Bexarotene 0-10 TSPY like 2 Homo sapiens 42-46 12399758-16 2002 CONCLUSION: This single-center study supports the safety and efficacy of bexarotene as both a monotherapy and a combination therapy for CTCL. Bexarotene 73-83 TSPY like 2 Homo sapiens 136-140 12399758-19 2002 When bexarotene is combined with other active CTCL therapies, higher RRs were achieved in patients with advanced disease, without unacceptable side effects. Bexarotene 5-15 TSPY like 2 Homo sapiens 46-50 12847736-1 2002 Bexarotene has recently been approved in the United States and Europe as a single orally administered retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Bexarotene 0-10 TSPY like 2 Homo sapiens 159-163 12006543-3 2002 EXPERIMENTAL DESIGN: CTCL cells were treated with 0.1, 1, and 10 microM bexarotene for 24, 48, 72, and 96 h. Apoptosis was determined by flow-cytometry analysis of sub-G(1) hypodiploid nuclei and annexin V binding populations. Bexarotene 72-82 TSPY like 2 Homo sapiens 21-25 12006543-7 2002 Bexarotene treatment decreased the protein levels of survivin, activated caspase-3, and cleaved poly(ADP-Ribose) polymerase, but had no obvious effect on expression of Fas/Fas ligand and bcl-2 proteins in all three CTCL lines. Bexarotene 0-10 TSPY like 2 Homo sapiens 215-219 12006543-8 2002 CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin. Bexarotene 13-23 TSPY like 2 Homo sapiens 92-96 12006543-9 2002 These findings support apoptosis as a mechanism for bexarotene therapy in CTCL. Bexarotene 52-62 TSPY like 2 Homo sapiens 74-78 11573857-1 2001 OBJECTIVE: To review the preclinical and clinical information related to oral bexarotene approved by the Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Bexarotene 78-88 TSPY like 2 Homo sapiens 210-214 11978140-8 2002 Recent novel developments in CTCL therapy include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL, and the topical gel formulation of bexarotene, which plays a role in treating localized lesions. Bexarotene 55-65 TSPY like 2 Homo sapiens 29-33 11978140-8 2002 Recent novel developments in CTCL therapy include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL, and the topical gel formulation of bexarotene, which plays a role in treating localized lesions. Bexarotene 184-194 TSPY like 2 Homo sapiens 29-33 11705358-5 2001 Although milestone drugs such as bexarotene have been approved by the FDA- for treatment of CTCL, other agents such as IL-12 may also have a place in treatment of the disease. Bexarotene 33-43 TSPY like 2 Homo sapiens 92-96 11902983-1 2002 OBJECTIVE: To evaluate the safety, dose tolerance, and efficacy of topical bexarotene gel in patients with early-stage cutaneous T-cell lymphoma (CTCL). Bexarotene 75-85 TSPY like 2 Homo sapiens 146-150 11902983-14 2002 CONCLUSIONS: Bexarotene gel was well tolerated, was easily self-applied, and had a substantial response rate in treating patients with early-stage CTCL. Bexarotene 13-23 TSPY like 2 Homo sapiens 147-151 11573857-5 2001 An evaluation focusing on the pharmacology of bexarotene and its role in the management of the different stages of CTCL was conducted. Bexarotene 46-56 TSPY like 2 Homo sapiens 115-119 11573857-6 2001 CONCLUSIONS: Bexarotene has demonstrated activity in the treatment of CTCL. Bexarotene 13-23 TSPY like 2 Homo sapiens 70-74 11573857-7 2001 The oral route of administration and the adverse effect profile of bexarotene appear to make this drug a favorable option for the treatment of CTCL. Bexarotene 67-77 TSPY like 2 Homo sapiens 143-147 11573857-9 2001 Phase III randomized studies are needed to determine the clinical benefits of bexarotene as monotherapy or combination therapy in the treatment of CTCL. Bexarotene 78-88 TSPY like 2 Homo sapiens 147-151 11249708-2 2000 The company launched the drug for the treatment of cutaneous T-cell lymphoma (CTCL), as Targretin capsules, in the US in January 2000 [359023]. Bexarotene 88-97 TSPY like 2 Homo sapiens 78-82 11331325-11 2001 Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL. Bexarotene 0-10 TSPY like 2 Homo sapiens 159-163 11520254-4 2001 The biological response-modifying treatment options currently used to treat CTCL are bexarotene, denileukin diftitox, interferon-alpha, interferon-gamma and interleukin-12, as well as extracorporeal photopheresis and phototherapy. Bexarotene 85-95 TSPY like 2 Homo sapiens 76-80 11249708-4 2000 The FDA approved Targretin capsules at the end of December 1999 for once-daily oral treatment of all stages of CTCL in patients refractory to at least one prior systemic therapy, at an initial dose of 300 mg/m2/day. Bexarotene 17-26 TSPY like 2 Homo sapiens 111-115 11707864-1 2000 The clinical experience with bexarotene for cutaneous T-cell lymphoma (CTCL) at our center is reviewed here. Bexarotene 29-39 TSPY like 2 Homo sapiens 71-75 11707864-4 2000 Four patients with refractory plaque CTCL were treated with bexarotene gel. Bexarotene 60-70 TSPY like 2 Homo sapiens 37-41 35221968-2 2022 Since the objective response rate of bexarotene is relatively high, with no racial differences, bexarotene can be administered to patients with phototherapy-resistant early CTCL as one of the first-line therapies in real-world clinical practice. Bexarotene 96-106 TSPY like 2 Homo sapiens 173-177 11702369-4 2000 In patients with refractory or persistent early stage cutaneous T cell lymphoma (CTCL), the overall response rate was 54% after oral bexarotene 300 mg/m2/day. Bexarotene 133-143 TSPY like 2 Homo sapiens 81-85 11702369-6 2000 An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL. Bexarotene 59-69 TSPY like 2 Homo sapiens 121-125 35084694-3 2022 The efficacy and safety of bexarotene and photo(chemo)therapy combination therapy were previously confirmed in Japanese patients with CTCL. Bexarotene 27-37 TSPY like 2 Homo sapiens 134-138 35221968-5 2022 In this report, drug eruptions in 2 patients with CTCL treated with bexarotene diagnosed by quantitative analysis of immunohistochemical staining by digital microscopy are described. Bexarotene 68-78 TSPY like 2 Homo sapiens 50-54 32207181-1 2020 Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world. Bexarotene 0-10 TSPY like 2 Homo sapiens 76-80 32207181-1 2020 Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world. Bexarotene 0-10 TSPY like 2 Homo sapiens 138-142 32207181-3 2020 Development of an appropriate protocol for bexarotene that can induce a consistent response for CTCL without severe AE (SAE) is needed. Bexarotene 43-53 TSPY like 2 Homo sapiens 96-100 32207181-10 2020 Our present study suggests that low-dose bexarotene plus NBUVB therapy is well-tolerated and could be one of the optimal therapies for advanced CTCL. Bexarotene 41-51 TSPY like 2 Homo sapiens 144-148 30903705-1 2019 OBJECTIVE: Central hypothyroidism (CH) is a well-known adverse effect of bexarotene treatment for cutaneous T-cell lymphoma (CTCL). Bexarotene 73-83 TSPY like 2 Homo sapiens 125-129 30903705-4 2019 DESIGN AND PATIENTS: Sixty-six Japanese patients with CTCL were retrospectively investigated by evaluating thyroid function during the early phase of bexarotene therapy. Bexarotene 150-160 TSPY like 2 Homo sapiens 54-58